Early cancer detection can change everything.
TeraDx takes a decisive step forward as it joins Zubi Labs, the impact venture builder of Zubi Group, founded by Iker Marcaide, to take its technology to the next level.
After years of research, the company presents its saliva-based test for the early detection of head and neck cancer, capable of delivering results in less than 24 hours with nearly 100% reliability.
- Standardized saliva collection
- qPCR analysis of microbial biomarkers
- Automated report compatible with existing hospital infrastructure
Head and neck cancer is the 7th most common cancer worldwide, with over 890,000 new cases each year and a projected 30% increase by 2030. TeraDx’s mission is clear: to make early detection faster, more accessible, and non-invasive.
With the support of Zubi Labs, the company is accelerating its path to clinical practice, bringing scientific innovation closer to hospitals and improving patient outcomes worldwide.
The founding team of TeraDx combines scientific excellence with business vision and execution capacity. It is led by Isabel Jiménez González (CEO), Iryna Biliaieva (Co-Founder), Dr. Vicente Navarro López (Founder & CSO), and Pol Hortal (Co-Founder / Managing Director at Zubi Labs) — a dedicated team committed to turning science into real clinical solutions that improve people’s lives.
cloud technology axon
For years, we have simplified capital allocation by reducing it to wha...
